Patents by Inventor Vladimir Ioffe

Vladimir Ioffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purified Detomidine, Process of Preparing and Methods of Use
    Publication number: 20210323929
    Abstract: The present disclosure relates to a purified detomidine HCl pharmaceutical product and to methods of preparation, validation of pharmaceutically acceptable product and use thereof.
    Type: Application
    Filed: July 18, 2019
    Publication date: October 21, 2021
    Inventors: Anton Frenkel, Vladimir Ioffe
  • N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF
    Publication number: 20170065576
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Application
    Filed: November 17, 2016
    Publication date: March 9, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF
    Publication number: 20160151345
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 2, 2016
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF
    Publication number: 20160151346
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Application
    Filed: February 2, 2016
    Publication date: June 2, 2016
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
    Patent number: 9284276
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: March 15, 2016
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF
    Publication number: 20160046582
    Abstract: The subject invention provides a mixture of Crystalline Laquinimod sodium particles, wherein (i) ?90% of the total amount by volume of the laquinimod sodium particles have a size of ?40 ?m or (ii) ?50% of the total amount by volume of the laquinimod sodium particles have a size of ?15 ?m and wherein: a) the mixture has a bulk density of 0.2-0.4 g/mL; b) the mixture has a tapped density of 0.40-0.7 g/mL; c) an amount of heavy metal in the mixture is no more than 20 ppm relative to the amount by weight of laquinimod sodium; d) an amount of MCQ in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of MCQCA in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; or f) an amount of MCQME in the mixture is no more than 0.12% relative to the amount of laquinimod sodium as measured by HPLC.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventors: Anton FEWNKEL, Avital LAZER, Vladimir IOFFE, Karl-Erik JANSSON, Ulf Tomas FRISTEDT
  • N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF
    Publication number: 20130217724
    Abstract: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 22, 2013
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Vladimir Ioffe, Konstantin Ulanenko, Avital Laxer, Muhammad Safadi, Danit Licht, Ioana Lovinger, Ulf Tomas Fristedt
  • Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
    Patent number: 7964751
    Abstract: Disclosed are enantiomers of amino-phenyl-acetic acid octadec-9-(Z)-enyl ester, and salts thereof, including pharmaceutical compositions, uses and a process for the manufacture thereof.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: June 21, 2011
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yaacov Herzig, Jeffrey Sterling, Vladimir Ioffe, Yuriy Raizi, Istvan Miskolczi, Andras Zekany
  • Enantiomers of amino-phenyl-acetic acid octadec-9-(z) enyl ester, their salts and their uses
    Publication number: 20080221209
    Abstract: Disclosed are enantiomers of amino-phenyl-acetic acid octadec-9-(Z)-enyl ester, and salts thereof, including pharmaceutical compositions, uses and a process for the manufacture thereof.
    Type: Application
    Filed: February 25, 2008
    Publication date: September 11, 2008
    Inventors: Yaacov Herzig, Jeffrey Sterling, Vladimir Ioffe, Yuriy Raizi, Istvan Miskolczi, Andras Zekany